Literature DB >> 15695826

BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.

Kathy Kamath1, Leslie Wilson, Fernando Cabral, Mary Ann Jordan.   

Abstract

The development of resistance to paclitaxel in tumors is one of the most significant obstacles to successful therapy. Overexpression of the betaIII-tubulin isotype has been associated with paclitaxel resistance in a number of cancer cell lines and in tumors, but the mechanism of resistance has remained unclear. Paclitaxel inhibits cancer cell proliferation by binding to the beta-subunit of tubulin in microtubules and suppressing microtubule dynamic instability, leading to mitotic arrest and cell death. We hypothesized that betaIII-tubulin overexpression induces resistance to paclitaxel either by constitutively enhancing microtubule dynamic instability in resistant cells or by rendering the microtubules less sensitive to the suppression of dynamics by paclitaxel. Using Chinese hamster ovary cells that inducibly overexpress either betaI- or betaIII-tubulin, we analyzed microtubule dynamic instability during interphase by microinjection of rhodamine-labeled tubulin and time-lapse fluorescence microscopy. In the absence of paclitaxel, there were no differences in any aspect of dynamic instability between the two beta-tubulin-overexpressing cell types. However, in the presence of 150 nm paclitaxel, dynamic instability was suppressed to a significantly lesser extent (suppressed only 12%) in cells overexpressing betaIII-tubulin than in cells overexpressing similar levels of betaI-tubulin (suppressed 47%). The results suggest that overexpression of betaIII-tubulin induces paclitaxel resistance by reducing the ability of paclitaxel to suppress microtubule dynamics. The results also suggest that endogenous regulators of microtubule dynamics may differentially interact with individual tubulin isotypes, supporting the idea that differential expression of tubulin isotypes has functional consequences in cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695826     DOI: 10.1074/jbc.M414477200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

1.  Paclitaxel-dependent cell lines reveal a novel drug activity.

Authors:  Anutosh Ganguly; Hailing Yang; Fernando Cabral
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

2.  Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs.

Authors:  Hailing Yang; Anutosh Ganguly; Fernando Cabral
Journal:  J Biol Chem       Date:  2010-08-09       Impact factor: 5.157

3.  Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Authors:  Guillaume Ploussard; Stéphane Terry; Pascale Maillé; Yves Allory; Nanor Sirab; Laurence Kheuang; Pascale Soyeux; Nathalie Nicolaiew; Estelle Coppolani; Bernard Paule; Laurent Salomon; Stéphane Culine; Ralph Buttyan; Francis Vacherot; Alexandre de la Taille
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

4.  CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.

Authors:  Chang Hoon Moon; Seung Ju Lee; Ho Yong Lee; Le Thi Kim Dung; Wha Ja Cho; HeeJeong Cha; Jeong Woo Park; Young Joo Min
Journal:  Invest New Drugs       Date:  2013-11-08       Impact factor: 3.850

Review 5.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

6.  Beta tubulin affects the aryl hydrocarbon receptor function via an Arnt-mediated mechanism.

Authors:  Tianmin Zhang; Xiaodong Wang; Annie Shinn; Jingjun Jin; William K Chan
Journal:  Biochem Pharmacol       Date:  2009-12-16       Impact factor: 5.858

7.  Gene expression profiles in mouse embryo fibroblasts lacking stathmin, a microtubule regulatory protein, reveal changes in the expression of genes contributing to cell motility.

Authors:  Danielle N Ringhoff; Lynne Cassimeris
Journal:  BMC Genomics       Date:  2009-07-30       Impact factor: 3.969

8.  The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.

Authors:  J Torin Huzil; Ke Chen; Lukasz Kurgan; Jack A Tuszynski
Journal:  Cancer Inform       Date:  2007-04-27

9.  Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.

Authors:  S Terry; G Ploussard; Y Allory; N Nicolaiew; F Boissière-Michot; P Maillé; L Kheuang; E Coppolani; A Ali; F Bibeau; S Culine; R Buttyan; A de la Taille; F Vacherot
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

10.  Novel microtubule-targeting agents - the epothilones.

Authors:  Kit L Cheng; Thomas Bradley; Daniel R Budman
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.